Slide 1: Second Quarter 2025 Results
Second Quarter 2025 Results August 7, 2025
Slide 2: Forward-looking Statements Non-GAAP Financial Information
Forward-looking Statements Non-GAAP Financial Information This presentation includes forward-looking statements, including forward-looking statements Enovis has provided in this presentation financial information that has not been prepared in accordance with within the meaning of the U.S. Private Se
Slide 3: Q2 2025 Highlights
Q2 2025 Highlights • +7% reported growth, +5% organic growth • +8% organic growth in Recon • +3% organic growth in P&R • Adjusted Earnings Per Share of +27% and positive cash flow, despite tariff headwinds • Launched key new products • ARG in Shoulder • Nebula and Surgical Impactor in Hip • ManaFuse
Slide 4: Q2 Reconstructive Segment Sales Performance
Q2 Reconstructive Segment Sales Performance Reconstructive Q2 Sales • WW performance back to above market growth • +8% organic growth Growth: +11% Y/Y, +8% organic • M/HSD global growth in both Hip/Knee and Extremities • U.S. organic growth of 6% • +10% Extremities growth fueled by ARG commercial ra
Slide 5: Q2 Prevention & Recovery Segment Sales Performance
Q2 Prevention & Recovery Segment Sales Performance P&R Q2 Sales • WW organic growth of 3% Growth: +5% Y/Y, +3% organic • Global Bracing growth of 3% • Adjusted EBITDA margin expansion +130bps • Positive mix and underlying productivity, EGX initiatives Recovery Sciences • Growing momentum for new pro
Slide 6: P&L Performance
P&L Performance Millions Q2 2024 Q2 2025 Millions H1 2024 H1 2025 Net Sales $525 $565 Net Sales $1,041 $1,123 Adj. Gross Profit $313 $341 Adj. Gross Profit $616 $686 Margin 59.6% 60.5% Margin 59.1% 61.1% Adj. EBITDA $90 $97 Adj. EBITDA $173 $196 Margin 17.2% 17.2% Margin 16.7% 17.5% Adj. EPS $0.62 $
Slide 7: Full Year 2025 Outlook
Full Year 2025 Outlook February May August Comments & Assumptions Reported Revenue $2.190-$2.220B $2.220-$2.250B $2.245-$2.275B • Global markets grow in line with historical averages aEBITDA $405-$415M $385-$395M $392-$402M • Organic Growth = ~6.25-6.75% Y/Y • HSD Recon growth, P&R stable at LSD Dep
Slide 8: Summary
Summary • Encouraging first half of the year, with strong fundamentals across key businesses • Above market Recon growth and new product launches position us to accelerate commercial momentum • Proactively and efficiently managing the dynamic global trade environment • Raising guidance for revenues
Slide 9: Appendix
Appendix enovis. Creating Better Together” 4
Slide 10: QTD Sales Bridge
QTD Sales Bridge © 2025 Enovis Corporation
Slide 11: QTD Sales Bridge
QTD Sales Bridge © 2025 Enovis Corporation
Slide 12: QTD Adjusted EPS Reconciliation
QTD Adjusted EPS Reconciliation © 2025 Enovis Corporation
Slide 13: QTD Adjusted EPS Reconciliation
QTD Adjusted EPS Reconciliation © 2025 Enovis Corporation
Slide 14: QTD Adjusted EBITDA Reconciliation
QTD Adjusted EBITDA Reconciliation © 2025 Enovis Corporation
Slide 15: QTD Adjusted Gross Margin Reconciliation
QTD Adjusted Gross Margin Reconciliation © 2025 Enovis Corporation
Slide 16: Q2'25 GAAP to Adjusted Non-GAAP Financial Measures
Q2’25 GAAP to Adjusted Non-GAAP Financial Measures © 2025 Enovis Corporation
Slide 17: Q2'24 GAAP to Adjusted Non-GAAP Financial Measures
Q2’24 GAAP to Adjusted Non-GAAP Financial Measures © 2025 Enovis Corporation
Slide 18: Enovis Creating Better Together
enovis. Creating Better Together”